Skip to main content

Paired Ends: Marc Stapley, Stan Rose, Michael Hunkapiller, Jeffrey Sklar, Martin Tolar

Premium

Illumina has appointed Marc Stapley as senior vice president and chief financial officer. Christian Henry, who had been serving dual positions as chief financial officer and general manager of Illumina's genetic analysis business, will continue to head the genetic analysis business. The change will go into effect on Jan. 20.

Stapley joins Illumina from Pfizer, where he served as senior vice president responsible for global financial processes and systems. Previously, he held various senior finance roles at Alcatel-Lucent. He also worked as finance director and controller for several groups at Cadence Design Systems. He holds a BS in mathematics from the University of Reading in the UK and is a member of the Institute of Chartered Accountants in England and Wales.


Pacific Biosciences has named Michael Hunkapiller CEO, replacing Hugh Martin who has resigned (see story, this issue).

Between 1995 and 2004, Hunkapiller served as president and general manager of Applied Biosystems (now Life Technologies). In 2004, he joined Alloy Ventures as a general partner, and led its investment in PacBio in 2005 when he joined PacBio's board of directors. He also serves on the boards of NuGen, Verinata Health, and RainDance Technologies.


Nabsys has made several appointments to its management team and scientific advisory board.

The company appointed Stan Rose to chief commercial officer. Previously, Rose served as CEO of NimbleGen where he oversaw the development, launch, and growth of the company's microarray product line from 2003 through the company's acquisition by Roche in 2007. Prior to NimbleGen, Rose co-founded Genetic MicroSystems, a microarray instrumentation company that was sold to Affymetrix in 2000. He directed PerkinElmer's and Applied Biosystems' PCR businesses during the 1990s. Rose holds a BA from Cornell University and a PhD from the Massachusetts Institute of Technology.

Jeffrey Sklar has joined Nabsys' scientific advisory board. He is a professor of pathology and laboratory medicine and director of the molecular diagnostics program, the molecular genetics pathology fellowship, and the molecular tumor profiling laboratory at Yale University School of Medicine. He did residency and post-doctoral training at Stanford University and also held tenured positions at Stanford and Harvard University before joining Yale. He holds an MD from Yale University School of Medicine and a PhD from Yale University.


Knome has made several new hires to its management team and scientific advisory board.

Martin Tolar will become the firm's CEO, replacing Jorge Conde, who will become chief strategy officer and continue to serve on the board of directors. Previously, Tolar served as CEO of Normoxys, where he helped advance the company's cancer therapeutics to clinical development. He has also served as chief scientific officer and chief business officer at CoMentis, and has held a variety of positions at Pfizer in its clinical development, strategic partnerships, and business development divisions. He served as assistant professor in the department of neurology at Yale University School of Medicine and as a research fellow at Massachusetts General Hospital. He holds a PhD in neuroscience.

Jonas Lee
, a founding member of Knome's board of directors will become chief marketing officer and head of consumer genomics. Previously, he founded and managed several companies including Redbrick Partners, Poindexter Systems, GiftCertificates.com, and Integrated Computing Engines. He has also served as a management consult with Bain & Company. He holds an MBA from Harvard Business School and a bachelor's degree from Brandeis University.

Marc Rubenfield will become the vice president of operations. Prior to joining Knome, he was responsible for the sequencing services product line, including the introduction of next-generation sequencing, at Beckman Coulter Genomics. He has also worked with Agencourt Biosciences and Genome Therapeutics Corporation.

Knome has appointed David Goldstein and Yaniv Erlich to its scientific advisory board.

Goldstein is a professor of molecular genetics and microbiology, a professor of biology, and director of the Center for Human Genome Variation at Duke University. Previously he was a professor of genetics at University College London, and is also an honorary professor at the Institute of Neurology at the University College London. He holds a PhD in biological sciences from Stanford University.

Erlich is the Andria and Paul Heady Family fellow and a principal investigator at Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology. He holds a bachelor's degree from Tel-Aviv University in Israel and a PhD from the School of Biological Sciences at Cold Spring Harbor Laboratory.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.